^
    CANCER:

    Uterine Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    nivolumab
    PD1 inhibitor
    dostarlimab-gxly
    		0
    PD1 inhibitor
    pembrolizumab
    tislelizumab
    zimberelimab
    retifanlimab-dlwr
    1
    Topoisomerase II inhibitor
    doxorubicin hydrochloride
    pegylated liposomal doxorubicin
    2
    DNA synthesis inhibitor
    cisplatin
    gemcitabine
    3
    mTOR inhibitor
    temsirolimus
    4
    VEGF-A inhibitor
    bevacizumab
    5
    HER2 inhibitor
    trastuzumab
    6
    Aromatase inhibitor, mTOR inhibitor
    everolimus + letrozole
    ribociclib
    		7
    CDK4 inhibitor, CDK6 inhibitor
    CDK4 inhibitor + CDK6 inhibitor
    abemaciclib
    8
    Estrogen receptor antagonist, Progesterone receptor agonist
    tamoxifen + megestrol
    9
    Bcl2 inhibitor, Tubulin inhibitor
    albumin-bound paclitaxel
    10
    Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel
    carboplatin + paclitaxel
    11
    Bifunctional alkylating agent
    ifosfamide
    12
    Topoisomerase I inhibitor
    topotecan
    13
    Tubulin polymerization promoter
    carboplatin
    14
    Bifunctional alkylating agent, DNA synthesis inhibitor
    cisplatin + ifosfamide
    15
    Estrogen receptor antagonist
    tamoxifen
    tamoxifen
    16
    Selective estrogen receptor degrader
    fulvestrant
    17
    DNA synthesis inhibitor, Thymidylate synthase inhibitor
    capecitabine + mitomycin
    18
    Progesterone receptor agonist
    megestrol
    olaparib
    		19
    PARP inhibitor
    niraparib
    talazoparib
    20
    PD-L1 inhibitor
    durvalumab
    avelumab
    21
    WEE1 inhibitor
    ZN-c3
    AZD1775
    Aromatase inhibitor
    		22
    Aromatase inhibitor
    anastrozole
    letrozole
    23
    HER2 inhibitor, HER2 dimerization inhibitor
    trastuzumab + pertuzumab
    24
    PD1 inhibitor, PARP inhibitor
    niraparib + dostarlimab-gxly
    25
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    26
    Multi-tyrosine kinase inhibitor
    pazopanib
    ponatinib
    pemigatinib
    		27
    FGFR inhibitor
    infigratinib
    futibatinib
    28
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    nivolumab + cabozantinib tablet
    anlotinib + sintilimab
    29
    KRAS G12C inhibitor
    sotorasib
    adagrasib
    30
    mTORC1 inhibitor, mTORC2 inhibitor
    CB-228
    31
    VEGF-A inhibitor, PARP inhibitor
    bevacizumab + rucaparib
    32
    XPO1 inhibitor
    selinexor
    33
    ATR inhibitor
    BAY 1895344
    34
    DKK1 protein inhibitor
    DKN-01
    35
    PIK3CA inhibitor, PI3Kδ inhibitor
    copanlisib
    36
    CAR-T immunotherapy
    TC-A101
    37
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    pembrolizumab + lenvatinib
    38
    Topoisomerase II inhibitor, Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor
    cisplatin + paclitaxel + doxorubicin hydrochloride
    39
    Topoisomerase II inhibitor, DNA synthesis inhibitor
    cisplatin + doxorubicin hydrochloride
    40
    Microtubule stabilizer, Tubulin polymerization promoter
    docetaxel
    carboplatin + docetaxel
    41
    Bifunctional alkylating agent, Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel + ifosfamide
    42
    Immunotherapy
    Immunotherapy
    43
    Immunotherapy, Tyrosine kinase inhibitor
    Immunotherapy + Tyrosine kinase inhibitor
    44
    Chemotherapy
    AIM
    45
    STAT3 inhibitor
    STAT3 inhibitor
    46
    CLDN18.2-targeted antibody-drug conjugate
    CLDN18.2-targeted antibody-drug conjugate
    47
    HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    BNT323
    fam-trastuzumab deruxtecan-nxki
    48
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
    erdafitinib
    49
    VEGFR inhibitor, PD1 inhibitor
    sintilimab + fruquintinib
    50
    EZH1 inhibitor, EZH2 inhibitor
    CPI-0209
    51
    Chk1 inhibitor, Chk2 inhibitor
    ACR-368
    52
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    53
    β-catenin inhibitor, CBP inhibitor, Wnt signalling pathway inhibitor
    PRI724
    54
    PI3K inhibitor, mTOR inhibitor
    LY3023414
    RTB101
    55
    PI3K inhibitor, MEK1 inhibitor, AKT inhibitor
    cobimetinib + RG7440
    56
    Microtubule stabilizer, Tubulin polymerization promoter, DNA synthesis inhibitor
    gemcitabine + docetaxel
    57
    Aromatase inhibitor, CDK4 inhibitor, CDK6 inhibitor
    palbociclib + letrozole
    58
    cRAF inhibitor, MEK inhibitor, BRAF inhibitor
    VS-6766
    59
    CDK2 inhibitor, CDK9 inhibitor
    CYC065
    60
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    pyrotinib
    afatinib
    61
    Folate receptor 1-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    PRO1184
    62
    HER2 inhibitor, EGFR inhibitor
    lapatinib
    trastuzumab + lapatinib
    63
    PARP inhibitor, TROP-2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    rucaparib + sacituzumab govitecan-hziy
    64
    FGFR inhibitor, VEGFR inhibitor, PDGFR α-β inhibitor, Tyrosine kinase inhibitor, PARP inhibitor
    rucaparib + E 3810
    65
    HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    ado-trastuzumab emtansine
    66
    PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
    imatinib
    STRO-002
    		67
    Folate receptor 1-targeted antibody-drug conjugate, Microtubule inhibitor
    mirvetuximab soravtansine-gynx
    MORAb-202
    68
    pan-RAF inhibitor, EGFR inhibitor
    BGB-283
    69
    PD-L1 inhibitor, VEGF-A inhibitor, PARP inhibitor
    bevacizumab + atezolizumab + rucaparib
    70
    Folate receptor 1-targeted antibody-drug conjugate, Microtubule inhibitor, PARP inhibitor
    rucaparib + mirvetuximab soravtansine-gynx
    71
    EZH2 inhibitor, HOTAIR inhibitor
    tazemetostat + AC1Q3QWB
    72
    PARP inhibitor, ATM kinase inhibitor
    olaparib + KU-55933
    73
    FGFR inhibitor, AKT inhibitor
    futibatinib + TAS-117
    futibatinib + MK-2206
    GDC-0941
    		74
    PI3K inhibitor
    MEN1611
    A66
    75
    Tyrosine kinase inhibitor
    PD173074
    76
    PI3Kβ inhibitor
    AZD6482
    GSK2636771
    77
    pan-RAF inhibitor
    AZ 628
    78
    SF3B1 inhibitor, RNA splicing modulator
    SSA
    79
    MEK inhibitor
    PD-0325901
    80
    FGFR inhibitor, VEGFR inhibitor, PDGFR inhibitor, pan-TRK inhibitor
    TKI258
    81
    PI3Kβ inhibitor, PI3K inhibitor
    A66 + AZD6482
    GSK2636771 + A66
    82
    PI3Kβ inhibitor, Apoptosis inducer
    TGX-221
    83
    TROP-2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    sacituzumab govitecan-hziy
    84
    HER2-targeted antibody-drug conjugate, DNA replication inhibitor
    DHES0815A
    85
    FGFR2 inhibitor
    RLY-4008
    86
    PI3K inhibitor, AKT inhibitor
    RG7440
    87
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor, PARP inhibitor
    olaparib + neratinib
    88
    BET inhibitor
    JQ-1
    89
    SOS1 inhibitor, MEK inhibitor
    trametinib + BI-3406
    90
    CD3 agonist, CLDN6 inhibitor
    CTIM-76
    91
    VEGF-A inhibitor, Folate receptor 1-targeted antibody-drug conjugate, Microtubule inhibitor
    bevacizumab + STRO-002
    No biomarker
    HER-2 expression
    HER-2 amplification
    HER-2 overexpression
    HER-2 positive
    HER-2 mutation
    ER positive
    ER expression
    MSI-H/dMMR
    FOLR1 expression
    ARID1A mutation
    KRAS G12C
    KRAS mutation
    KRAS G12D
    BRCA1 mutation
    YWHAE-NUTM2B translocation
    CTNNB1 mutation
    TP53 mutation
    PTEN mutation
    POLE V411L
    POLE P286R
    PTEN-L
    PTEN deletion
    POLE mutation
    TP53 wild-type
    TP53 overexpression
    TP53 amplification
    TMB-H
    MSH6 F1088fs
    PALB2 mutation
    MLH1 deletion
    FGFR mutation
    MSI-H/dMMR + MLH1 deletion
    MSH6 mutation
    FGFR fusion
    PALB2 deletion
    PGR positive
    PIK3CA mutation
    FGFR2 S252W
    KIT expression
    MLH1 deletion+ PMS2 deletion
    FGFR3-TACC3 fusion
    CXCL10 elevation
    YWHAE-NUTM2A translocation
    MSH2 deletion
    LRP1B mutation
    AKT1 mutation + mTOR mutation
    MSI-H/dMMR + TMB-H + PD-L1 negative
    FGFR2-OFD1 fusion
    FGFR2-BICC1 fusion
    ALPP expression
    FAT2 mutation
    MLH1 methylation + MSI-H/dMMR + TMB-H
    MLH1 methylation + MSI-H/dMMR
    MSH2 deletion + MSH6 deletion
    NTRK1 fusion
    HRD + BRCA2 mutation
    HRD + BRCA1 mutation
    TSC2 mutation
    TSC1 mutation
    EGFR E690K
    NTRK2 fusion
    NTRK3 fusion
    AKT1 mutation
    BRCA2 mutation
    ER positive + PGR positive
    PD-L1 expression
    PIK3R1 mutation
    ERBB3 amplification
    CCNE1 overexpression
    CXCL9 elevation
    ATM PI2629fs*
    MCL1 amplification
    DKK1 overexpression
    FGFR2 N549K
    ATM overexpression
    FGFR2 B252W
    FGFR2 K310R
    ERBB3 expression
    FGFR2 mutation
    FGFR2 N550K
    PIK3CA H1047R
    FGFR2 expression
    TROP2 overexpression
    MRE11A mutation
    HRAS mutation
    HRD Signature-3
    NRAS mutation
    BRD4 overexpression
    CLDN18.2 expression
    SF3B1 K666N
    CLDN6 expression
    PIK3CA mutation + PTEN mutation + KRAS mutation
    FGFR3 mutation
    SOX17 overexpression
    CDKN1A overexpression
    PIK3CA mutation + KRAS mutation
    STAT3 mutation
    PD-L2 overexpression